Study details
Enrolling now
The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)
Yale University
NCT IDNCT06070649ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
63
Study length
about 12 months
Ages
21–65
Locations
1 site in CT
What this study is about
Researchers are testing a treatment for Alcohol Use Disorder (AUD) using the psychedelic drug DMT. The trial will investigate if this treatment is safe and effective in reducing alcohol consumption.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive 0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion
- 2.Receive 0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion
- 3.Take 25 mg Diphenhydramine (5 min) + Normal Saline
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Injection / IVInjection / IV
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
diphenhydramine
Drug routes
infusion, intravenous
Endpoints
Primary: Safety and tolerability of DMT in women and men with AUD
Body systems
Psychiatry / Mental Health